Zejula-Bevacizumab Combo Delays Progression in Relapsed Ovarian Cancer, Trial Finds

Zejula-Bevacizumab Combo Delays Progression in Relapsed Ovarian Cancer, Trial Finds
A combination of bevacizumab and Zejula (niraparib) is significantly better than Zejula alone at extending the time without disease progression in people with platinum-sensitive relapsed ovarian cancer, findings from a clinical trial show. The combination also delayed the need for subsequent treatment by prolonging time without disease worsening, and showed a trend toward better survival rates, the researchers noted. These data were shared at the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting — which was held virtually due to the COVID-19 pandemic — in the study, "Final survival analysis of NSGO-AVANOVA2/ENGOT-OV24: Combination of niraparib and bevacizumab versus niraparib alone as treatment of recurrent platinum-sensitive ovarian cancer—A randomized controlled chemotherapy-free study." Bevacizumab, marketed as Avastin among other brand names, is an anti-angiogenic therapy that works b
Subscribe or to access all post and page content.